Cogent Biosciences, Inc. COGT
29.14 USD -0.26 (-0.88%)
At closeNov 12, 2026, 4:00 PM EST
29.14 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
28.61 Day range 29.78
27.74 52-week range 43.73
- YTD
- -17.96%
- 1 year
- -17.36%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $56 HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $55 to $56.
benzinga.com If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 19.53% on an annualized basis producing an average annual return of 30.65%. Currently, Cogent Biosciences has a…- benzinga.com Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 14.59% on an annualized basis producing an average annual return of 26.37%. Currently, Cogent Biosciences has a…
benzinga.com $1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 16.44% on an annualized basis producing an average annual return of 28.63%. Currently, Cogent Biosciences has a…- benzinga.com Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 18.64% on an annualized basis producing an average annual return of 30.55%. Currently, Cogent Biosciences has a…
benzinga.com Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $55 price target.
benzinga.com FDA Accepts Cogent Biosciences' NDA For Bezuclastinib In Patients With Advanced Systemic Mastocytosis NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSMPDUFA target action date set for…
benzinga.com Cogent Biosciences Enters Commercial Supply Agreement With Hovione On Sept 1, 2026; To Purchase Minimum Percentages Of Bezuclastinib Products From Hovione; Agreement Effective For Five-Year Term With Automatic Two-Year Renewals On September 1, 2026, Cogent Biosciences, Inc. (the "Company") entered into a Commercial Supply Agreement (the "Agreement") with Hovione FarmaCiencia S.A. ("Hovione") to manufacture bezuclastinib- benzinga.com $100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 22.44% on an annualized basis producing an average annual return of 33.55%. Currently, Cogent Biosciences has a…
benzinga.com Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55 Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $52 to $55.
benzinga.com Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52 Guggenheim analyst Michael Schmidt maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $45 to $52.- benzinga.com Cogent Biosciences Files Prospectus for At-The-Market Offering Of Up To $400M In Common Stock Up to $400,000,000COMMON STOCKWe have entered into a Sales Agreement with Guggenheim Securities, LLC ("Guggenheim Securities"), dated May 6, 2022, as amended by that certain Amendment No. 1 to Sales…
benzinga.com Cogent Biosciences Q2 EPS $(0.52) Beats $(0.57) Estimate Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 1.89 percent increase over losses of…- benzinga.com If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 28.96% on an annualized basis producing an average annual return of 40.76%. Currently, Cogent Biosciences has a…
- benzinga.com Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Advanced Systemic Mastocytosis Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has submitted its New Drug Application…
- benzinga.com Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European Hematology Association Congress, June 11-14 We're encouraged by the preclinical data from our next-generation JAK2 program being presented at EHA today," said Andrew Robbins, Cogent's President and Chief Executive Officer. "This highly…
- benzinga.com Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
- benzinga.com Cogent Biosciences Says FDA Accepts NDA For Bezuclastinib In Combination With Sunitinib For Patients With GIST With PDUFA Target Action Date Of November 30 NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30,
- benzinga.com HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $55 HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $52 to $55.
- benzinga.com Cogent Biosciences Q1 EPS $(0.53) Beats $(0.56) Estimate Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 1.92 percent decrease over losses of…
benzinga.com Cogent Biosciences Announces Poster Presentations Of Preclinical Data From The KRAS And ErbB2 Pipeline Programs At The American Association For Cancer Research Meeting, April 17-22 Poster DetailsTitle: Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with selectivity for mutant KRAS over HRAS and NRASSession Category: Experimental and Molecular…- benzinga.com Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Patients With Gastrointestinal Stromal Tumors Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the completion of the submission of its…
benzinga.com Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
benzinga.com Cogent Biosciences Stock Climbs After FDA Accepts Key Drug Application FDA accepts Cogent Biosciences' NDA for bezuclastinib in NonAdvSM. PDUFA date set for Dec 30, 2026. COGT stock rises on the news.- benzinga.com Reported Saturday, Cogent Biosciences Highlights SUMMIT Data At AAAAI 2026, Bezuclastinib Delivers –32.0 Point Mean TSS Reduction At 48 Weeks With 99% Achieving ≥50% Serum Tryptase Reduction Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase…
- benzinga.com Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $52 Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $39 to $52.
- benzinga.com Cogent Biosciences Q4 EPS $(0.61) Misses $(0.53) Estimate Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.53) by 15.97 percent. This is a 577.78 percent decrease over losses…
benzinga.com Why Is Pfizer Stock Rising Tuesday? Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor Fitzgerald. The firm raised its target to $27 from $24, providing a catalyst for…
benzinga.com Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag The FDA granted breakthrough status to Cogent's GIST drug combo after a trial showed it cut disease progression or death risk by 50% compared with current treatment.- benzinga.com The FDA Grants Breakthrough Therapy Designation To Cogent Biosciences' Bezuclastinib Plus Sunitinib For Gastrointestinal Stromal Tumor Patients Previously Treated With Imatinib This Breakthrough Therapy Designation is based on results from the PEAK trial which demonstrated a substantial and highly statistically significant clinical benefit on the primary endpoint of…
- benzinga.com Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.
- benzinga.com Cogent Biosciences To Initiate New Drug Application Submission For Bezuclastinib Under Real-Time Oncology Review - PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and…
- benzinga.com Cogent Biosciences Highlights 2026 Milestones For Bezuclastinib And Precision Therapies Portfolio New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026 NDA submission for GIST on track for April 2026; bezuclastinib has the potential to…
- benzinga.com HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $52 HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $50 to $52.
- benzinga.com Cogent Biosciences Submits New Drug Application To FDA For Bezuclastinib In NonAdvanced Systemic Mastocytosis Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has submitted its New Drug Application…
- benzinga.com JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $67 JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $65 to $67.
- benzinga.com Cogent Biosciences Reports APEX Trial Results for Bezuclastinib in Advanced Systemic Mastocytosis Cogent Biosciences, Inc. (NASDAQ:COGT) today announced positive top-line results from the registration-directed APEX Part 2 clinical trial of bezuclastinib in patients with advanced systemic…
- benzinga.com Reported Saturday, Cogent Biosciences Highlights Bezuclastinib Rapid, Deep, Sustained Improvement In Objective Measures Of Mast Cell Burden In SUMMIT NonAdvSM Study Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline --Bezuclastinib…
- benzinga.com HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $50 HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $21 to $50.
- benzinga.com Baird Maintains Neutral on Cogent Biosciences, Raises Price Target to $34 Baird analyst Colleen Kusy maintains Cogent Biosciences (NASDAQ:COGT) with a Neutral and raises the price target from $14 to $34.
- benzinga.com Leerink Partners Maintains Outperform on Cogent Biosciences, Raises Price Target to $50 Leerink Partners analyst Andrew Berens maintains Cogent Biosciences (NASDAQ:COGT) with a Outperform and raises the price target from $18 to $50.
- benzinga.com Cogent Biosciences Announces $200M Senior Notes Offering, $200M Common Stock Offering Cogent Biosciences, Inc. ("Cogent") (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Gold Jumps Over 2%; Dole Shares Gain After Q3 Results 
benzinga.com Cogent Biosciences' Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trial Cogent Biosciences stock rises as bezuclastinib plus Sutent shows 50% lower progression risk and strong efficacy in Phase 3 GIST trial.
benzinga.com Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday 
benzinga.com S&P 500 Surges 1%; Tyson Foods Posts Upbeat Earnings - benzinga.com Cogent Biosciences Combination Of Bezuclastinib Plus Sunitinib In Phase 3 PEAK Study Reaches Median Progression Free Survival Of 16.5 Months; Company On Track To Submit New Drug Application To US FDA For Bezuclastinib In Intolerant Gastrointestinal Stromal Tumors Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported positive data from its Phase 3 PEAK trial…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $21 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $21 price target.